Affimed Therapeutics B.V. - AFMD
Seite 24 von 66 Neuester Beitrag: 19.07.24 09:42 | ||||
Eröffnet am: | 16.09.14 15:03 | von: NikGol | Anzahl Beiträge: | 2.646 |
Neuester Beitrag: | 19.07.24 09:42 | von: iTechDachs | Leser gesamt: | 552.225 |
Forum: | Hot-Stocks | Leser heute: | 421 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 21 | 22 | 23 | | 25 | 26 | 27 | ... 66 > |
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, today announced that its Chief
Executive Officer, Dr. Adi Hoess, will present at the SVB Leerink 9(th)
Annual Global Healthcare Conference on Tuesday, February 25, 2020 at
10:30 a.m. Eastern Time.
A live webcast of the presentation can be accessed under the "Investors"
section of Affimed's website at
https://www.globenewswire.com/...6vWKMtGjcYo-n1NU6oTr2ZzlzTjJErcpmJU=
https://www.affimed.com/investors/webcasts_cp/ and will be available for
30 days following the event.
WO2020043670 - CRYOPRESERVED NK CELLS PRELOADED WITH AN ANTIBODY CONSTRUCT
sollte Affimed umfassenden Patentschutz der eigenen Engager Antikörperkonstrukten in Mischung mit vorgefertigten Zellprodukten verschiedenster NK-Zellen z.B. von Fate oder NK oder deren CAR-NK Varianten bieten.
https://clinicaltrials.gov/ct2/...try=&state=&city=&dist=
Zumindest bei AFM13 sind neue Studienorte dazu gekommen. Für shorter (ein weiterer Grund für fallende Kurse) eine schöne Spielwiese, insbesondere da bei Biotechs Verspätungen schon fast die Regel sind. Muss noch einmal nachforschen, welche Nachrichten anstehen könnten. Ich bin mir auch nicht sicher, ob jemand anderes in eine Kombistudie einsteigt, womit Geld und Aufmerksamkeit für affimed verbunden wäre, wenn Genetech/Roche hier schon den Fuss in der Tür hat.
Vielleicht hilft der anvisierte Termin weiter, womit man rechnen kann noch in diesem Kalenderjahr:
"Affimed N.V. is estimated to report earnings on 03/25/2020. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.23. The reported EPS for the same quarter last year was $0.17."
https://www.nasdaq.com/market-activity/stocks/afmd/earnings
Anregungen zu vielleicht zu erwartende news in diesem Jahr gerne gesehen.
"today announced the appointment of Dr. Arndt Schottelius as Chief Scientific Officer, effective April 2020."
und was er schon mit entdeckt und entwickelt hat!
Nur hier-> https://www.finanzen.net/termine/unternehmen/quartalszahlen
Dr. Adi Hoess will conduct virtual one-on-one meetings with institutional investors at the 2020 Wells Fargo Biotech Corporate Access Day on Tuesday, April 7, 2020."
“The unprecedented and expanding COVID-19 global health crisis will require an extraordinary amount of healthcare resources that we expect will have an impact on our clinical trials. As circumstances around the COVID-19 pandemic continue to rapidly evolve, we are continuously assessing possible effects on our clinical trials and adapting the risk mitigation measures we have implemented to date, and will update trial timelines after we have more visibility on the length and extent of the COVID-19 crisis.”
Die Produktionskapazitäten zur Behandlung der Patienten sind bisher nicht unterbrochen, 39 sites involviert mit AFM 13 ...
"Preclinical research for ongoing internal and partnered programs under the company’s collaboration with Genentech remains unimpacted by the COVID-19 pandemic at this time."
Am 28. April gibt es den Jahresbericht und eine Konferenz dazu.
Hoffen wir mal, dass irgendwo hier der Boden im Kurs gefunden wird. Die noch folgende Investorenkonferenz bringt irgendwie das Gespenst Geldbeschaffung auf. AFM 24 ist ja noch früh ...
Eine Info am Rande - gestern wurde ein Block knapp unter 3 Millionen zu 1,50 Dollar an der Nasdaq gehandelt ... vielleicht gibt es ja eine Meldung dazu in naher Zeit.
Die Ernennung von Arndt Schottelius und die Info dazu empfand ich als sehr positiv!
könnte ein schönes Muster für zukünftige Affimed NK-Zell Therapien abgeben. 25 Millionen US Dollar vorab in Bargeld und Aktien pro Zielantigen mit bis zu 450 Millionen Dollar an Entwicklungs-/Zulassungs- sowie weiteren 300 Millionen an möglichen Verkaufs-Meilensteinen plus 2-stellige Umsatzbeteiligung bei vermarkteten Produkten.
AFM24, designed to activate innate immunity to broadly target EGFR-expressing solid tumors regardless of mutational status, has the potential to improve efficacy and safety over currently available EGFR-targeted therapies
AFM24 is the first innate cell redirecting immuno-oncology therapeutic dosed in solid tumor patients
Heidelberg, Germany, April 16, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the first patient was successfully dosed in a Phase 1/2a clinical trial of AFM24, a first in human study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies. AFM24, a tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-binding innate cell engager, is novel due to its activation of innate immunity to kill solid tumors, inducing both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as compared to other therapies that rely heavily on signal or checkpoint inhibition.
“Today is a landmark day for Affimed and, more importantly, for patients whose solid tumors continue to progress,” said Dr. Adi Hoess, Chief Executive Officer of Affimed. “This major milestone marks the first time a patient with solid tumors has been dosed with an innate cell engager. AFM24 has demonstrated preclinically the ability to bridge NK cells and macrophages to EGFR-expressing tumor cell lines, and to induce lysis through ADCC and ADCP, respectively, independent of RAS mutational status. We look forward to the continued study of this novel agent and further validating its safety and efficacy through this human clinical trial.”
“Initiation of dosing in the first in human clinical trial of AFM24 is exciting news for the broad set of patients with hard to treat EGFR-expressing cancers,” said Dr. Anthony El-Khoueiry, Phase I program director at the USC Norris Comprehensive Cancer Center and Keck School of Medicine, and principal investigator for the study. “While available EGFR therapies have improved the lives of patients, new therapeutic options are needed that are broadly efficacious, easier for patients to tolerate and can also address the issue of resistance associated with currently available treatments.”
The study is an open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study to evaluate AFM24 as monotherapy in adult patients with advanced solid malignancies known to be EGFR-positive. The aim of the dose escalation phase is the determination of the maximum tolerated dose and the establishment of a recommended Phase 2a dose. The dose expansion phase is intended to collect preliminary evidence of efficacy and to further confirm the safety of AFM24. For more information including eligibility criteria, visit www.clinicaltrials.gov, using Identifier NCT04259450.